A method for constructing a TrpA1-3xFLAG-P2A-iCre gene knock-in mouse

By precisely knocking in the 3×FLAG-P2A-iCre sequence at the TrpA1 locus using CRISPR/Cas9 technology and combining it with the Cre-loxP system, the problem of detecting and validating TrpA1-positive cells has been solved, achieving highly sensitive and specific labeling and providing a tool for genetic lineage tracing and functional research of TrpA1-positive cells.

CN122326685APending Publication Date: 2026-07-03ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202610770705.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-01
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Existing technologies lack a labeling system that facilitates the detection and verification of TrpA1-positive cells, and have limited means of functional verification, making it impossible to achieve high-sensitivity and specific detection of TrpA1 protein and to perform in vivo tracing.

Method used

The CRISPR/Cas9 technology was used to precisely knock in the 3×FLAG-P2A-iCre sequence at the TrpA1 locus. Combined with the Cre-loxP system, the genetic markers and functions of TrpA1 positive cells were studied. The TrpA1 protein was detected by FLAG tagging and the genetic lineage was traced using Cre recombinase.

Benefits of technology

It achieves highly sensitive detection and specific labeling of TrpA1 protein, ensures spatiotemporally specific expression of Cre recombinase, and provides a tool for genetic lineage tracing and functional studies of TrpA1-positive cells, applicable to pain and inflammation research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122326685A_ABST
    Figure CN122326685A_ABST
Patent Text Reader

Abstract

This invention discloses a method for constructing a TrpA1-3×FLAG-P2A-iCre gene knock-in mouse. A fragment containing a 3×FLAG tag, a P2A sequence, and an iCre recombinase sequence is inserted into the 27th exon region of the mouse TrpA1 gene using a CRISPR / Cas9 system, achieving genetic labeling and Cre functionalization in TrpA1-expressing cells. The donor vector provided by this invention contains a 5' homologous arm and a 3' homologous arm that are homologous to the TrpA1 genome sequence. Stably inherited knock-in mice are obtained by microinjecting the CRISPR / Cas9 system and the donor vector into fertilized eggs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of genetic engineering and model animal construction technology, and in particular to a method for constructing a TrpA1-3×FLAG-P2A-iCre gene knock-in mouse using CRISPR / Cas9 technology, which can be used for genetic marker and functional studies of TrpA1 positive cells. Background Technology

[0002] TrpA1 (Transient Receptor Potential Ankyrin 1) is a member of the transient receptor potential (TRP) superfamily and is a non-selective cation channel primarily expressed in sensory neurons such as the dorsal root ganglion (DRG) and trigeminal ganglion. Furthermore, studies have shown that TrpA1 expression signals can also be detected in the central nervous system, including some cells in brain regions such as the cerebral cortex and hippocampus. TrpA1 plays an important role in various physiological and pathological processes, including nociceptive sensation, inflammatory pain, neurogenic inflammation, respiratory diseases, and temperature sensation.

[0003] The TrpA1 channel can be activated by a variety of endogenous and exogenous stimuli, including pungent substances (such as allyl isothiocyanate in mustard), environmental irritants, reactive oxygen species, lipid peroxidation products, and certain inflammatory mediators. Therefore, TrpA1 is considered an important target for pain and inflammation research and a potential therapeutic target for developing novel analgesics.

[0004] Currently, research on TrpA1-positive cells mainly relies on traditional techniques such as immunohistochemical staining and in situ hybridization. However, these methods have drawbacks such as insufficient specificity, limited sensitivity, and inability to perform in vivo tracking. Although TrpA1-Cre mice have been developed, there is a lack of a tagging system that facilitates detection and verification, and functional verification methods are limited.

[0005] CRISPR / Cas9 technology, as a next-generation gene editing tool, boasts advantages such as ease of operation, high efficiency, and strong specificity, and has been widely applied to gene knock-in, knockout, and other genetic modifications. The Cre-loxP system is currently the most widely used conditional gene editing system, capable of regulating gene expression under specific spatiotemporal conditions. FLAG tags, as commonly used protein tags, are characterized by their small molecular weight, high specificity, and ease of detection. The P2A sequence is a self-cleaved peptide sequence that enables the co-expression of multiple genes without forming fusion proteins.

[0006] However, a TrpA1 gene knock-in mouse model that simultaneously integrates a FLAG tag and Cre recombinase is currently lacking. Such a model would not only enable TrpA1 protein detection via the FLAG tag but also facilitate genetic lineage tracing and conditional gene manipulation of TrpA1-positive cells via the Cre recombinase, providing a powerful tool for in-depth research into the role of TrpA1 in the sensory nervous system, pain mechanisms, and related diseases. Therefore, there is an urgent need to establish an efficient and stable method for constructing a TrpA1-3×FLAG-P2A-iCre gene knock-in mouse model. Summary of the Invention

[0007] The purpose of this invention is to overcome the shortcomings of the prior art and provide a method for constructing a TrpA1-3×FLAG-P2A-iCre gene knock-in mouse. This method uses CRISPR / Cas9 technology to achieve precise knock-in at the TrpA1 gene locus, providing a reliable tool for the labeling, tracing, and functional study of TrpA1 positive cells.

[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows: a method for constructing a TrpA1-3×FLAG-P2A-iCre gene knock-in mouse, comprising the following steps:

[0009] S1. Design and in vitro transcribe and synthesize gRNA and Cas9 mRNA targeting the end of exon 27 of the TrpA1 gene;

[0010] S2. Construct a targeting vector containing 3×FLAG-P2A-iCre insert sequences and homologous arms;

[0011] S3. gRNA, Cas9 mRNA and the targeting vector were co-microinjected into C57BL / 6 mouse zygotes;

[0012] S4. Extract DNA from the tails of F0 generation mice, and screen positive individuals by PCR amplification and sequencing;

[0013] S5. Cross F0 generation positive mice with wild-type mice to obtain F1 generation heterozygous mice;

[0014] S6. Genotyping of F1 generation mice;

[0015] S7. TrpA1-3×FLAG-P2A-iCre heterozygous mice were crossed with Cre reporter mice, and the function of Cre recombinase and the distribution of TrpA1-expressing cells were verified by immunofluorescence or immunohistochemical staining.

[0016] As a preferred embodiment of the method described in this invention, the target sequences of the gRNA in step S1 are AAGACACAGAACTAAAAGTC and AGACACAGAACTAAAAGTCC, which are designed at the end of exon 27 of the TrpA1 gene to achieve precise gene editing.

[0017] As a preferred embodiment of the method described in this invention, the targeting vector in step S2 comprises a 5' homologous arm, a 3×FLAG tag coding sequence, a P2A autorepeptide sequence, an iCre recombinase coding sequence, and a 3' homologous arm, thereby achieving site-specific integration of exogenous fragments through homologous recombination.

[0018] As a preferred embodiment of the method described in this invention, the PCR identification in step S4 uses three pairs of primers to amplify the 5' end, 3' end, and internal sequence of the inserted fragment, respectively, to ensure the accuracy and integrity of the knock-in.

[0019] As a preferred embodiment of the method described in this invention, the functional verification in step S7 involves sectioning and immunostaining tissues (such as brain tissue) known to express TrpA1, and confirming the functionality and expression specificity of Cre recombinase by tdTomato fluorescence signal.

[0020] This invention achieves FLAG tagging of endogenous TrpA1 protein and specific expression of Cre recombinase in TrpA1-positive cells by inserting a 3×FLAG-P2A-iCre sequence before the stop codon of the TrpA1 gene, providing an efficient tool for studying the biological function of TrpA1.

[0021] The TrpA1-3×FLAG-P2A-iCre gene knock-in mouse constructed in this invention can be applied in neurobiology, pain mechanism research, sensory physiology, and Cre-loxP system-related research.

[0022] The beneficial effects of this invention are:

[0023] (1) The precise knock-in of the TrpA1 locus was achieved using CRISPR / Cas9 technology, which preserved the expression regulation pattern of the endogenous gene and ensured the spatiotemporal specificity of Cre recombinase expression.

[0024] (2) The introduction of the 3×FLAG tag provides a highly sensitive and specific tool for the detection of TrpA1 protein, which facilitates experiments such as immunoblotting, immunoprecipitation and immunohistochemistry.

[0025] (3) The expression of iCre recombinase allows this mouse to be used in conjunction with various loxP-labeled reporter genes or conditional knockout mice to achieve genetic lineage tracing and functional studies of TrpA1 positive cells;

[0026] (4) The application of P2A auto-peptide ensures that the FLAG-tagged TrpA1 protein and iCre recombinase function independently and do not interfere with each other;

[0027] (5) The mouse model constructed in this invention provides an important tool for research fields such as pain, inflammation, and sensory conduction, and has broad application prospects. Attached Figure Description

[0028] Figure 1 This is a schematic diagram of the TrpA1-3×FLAG-P2A-iCre gene knock-in strategy of the present invention.

[0029] Figure 2 A is a schematic diagram of the PCR identification strategy for F0 generation mice;

[0030] wild type: No target band detected; A single wild-type band can be detected;

[0031] Heterozygote: The target band can be detected; A single wild-type band can be detected;

[0032] Homozygous: The target band can be detected; No single wild-type bands were detected.

[0033] Figure 2 Image B is an electrophoresis diagram of the PCR identification results of F0 generation mice. The results show that mice numbered 118, 119, 120, 122, 124, and 125 all obtained amplification products of the expected size at all three detection sites. In the figure, the numbers represent the mouse tail numbers, P is the positive control, WT is the wild-type control (C57BL / 6), N is the negative control (no template control), and M is the DNA molecular weight standard.

[0034] Figure 3 Immunofluorescence staining images of brain tissue sections from the hybrid offspring of TrpA1-3×FLAG-P2A-iCre mice and Rosa26-LSL-tdTomato (Ai14) reporter mice show the distribution of tdTomato-positive cells. The TrpA1-3×FLAG-P2A-iCre construct expresses Cre recombinase in specific cells, and the Ai14 system is a Cre-dependent tdTomato reporter system used to label Cre-positive cells, enabling visualization of the target cells. Detailed Implementation

[0035] To more clearly illustrate the technical solution of the present invention, the construction process of the TrpA1-3×FLAG-P2A-iCre gene knock-in mouse is described in detail below with reference to specific embodiments. However, this embodiment is only used to illustrate the technical solution of the present invention and does not limit the scope of protection of the present invention.

[0036] The CRISPR / Cas9 system used in this invention can specifically target the end of exon 27 of the mouse TrpA1 gene, achieving precise integration of the 3×FLAG-P2A-iCre sequence through homologous recombination-mediated gene knock-in. All mice were housed in an SPF-grade animal facility (temperature 22–25°C, humidity 40–60%, 12:12h light / dark cycle) and provided with standard feed and water.

[0037] Example 1

[0038] Step S1: In vitro transcription of gRNA and Cas9 mRNA

[0039] Two gRNAs targeting the end of exon 27 of the TrpA1 gene were designed, with the following targeting sequences:

[0040] gRNA1: 5'-AAGACACAGAACTAAAAGTC-3'

[0041] gRNA2: 5'-AGACACAGAACTAAAAGTCC-3'

[0042] The gRNA template was cloned into an in vitro transcription vector and transcribed in vitro using T7 RNA polymerase. Simultaneously, Cas9 mRNA was transcribed in vitro using a commercial in vitro transcription kit (e.g., mMESSAGE mMACHINE T7 Ultra kit). The transcription product was treated with DNase I to remove template DNA, then purified using an RNA purification kit (e.g., RNeasy Mini Kit), dissolved in RNase-free water, adjusted to a concentration of 1 μg / μl, and stored at -80°C for later use.

[0043] Step S2: Construction of the target carrier

[0044] A TrpA1-3×FLAG-P2A-iCre targeting vector was constructed, which contains the following elements:

[0045] (1) 5' homologous arm: approximately 1.5 kb in length, located in the genome sequence upstream of the stop codon of exon 27 of the TrpA1 gene;

[0046] (2) 3×FLAG tag encoding sequence: Encodes three tandem FLAG tabletops (DYKDDDDK).

[0047] (3) P2A auto-cleaved peptide sequence: derived from the 2A peptide of porcine Teschovirus-1, the sequence is GSG-ATNFSLLKQAGDVEENPGP;

[0048] (4) iCre recombinase coding sequence: The Cre recombinase gene with codon optimization improves its expression efficiency in mammalian cells;

[0049] (5) 3' homologous arm: approximately 1.5 kb in length, located in the genome sequence downstream of the stop codon of exon 27 of the TrpA1 gene.

[0050] The inserted sequence (3×FLAG-P2A-iCre) is shown in SEQ ID NO:1. After the vector was constructed, its correctness was verified by enzyme digestion and sequencing. The plasmid DNA was then prepared and purified in large quantities, and the concentration was adjusted to 100 ng / μl.

[0051] SEQ ID NO:1 (3×FLAG-P2A-iCre)

[0052] GAC TAC AAA GAC CAT GAC GGT GAT TAT AAA GAT CAT GAT ATC GAT TAC AAGGAT GAC GAT GAC AAG GGA AGC GGA GCT ACT AAC TTC AGC CTG CTG AAG CAG GCT GGCGAC GTG GAG GAG AAC CCT GGT CCT ATG GTG CCC AAG AAG AAG AGG AAA GTC TCC AACCTG CTG ACT GTG CAC CAA AAC CTG CCT GCC CTC CCT GTG GAT GCC ACC TCT GAT GAAGTC AGG AAG AAC CTG ATG GAC ATG TTC AGG GAC AGG CAG GCC TTC TCT GAA CAC ACCTGG AAG ATG CTC CTG TCT GTG TGC AGA TCC TGG GCT GCC TGG TGC AAG CTG AAC AACAGG AAA TGG TTC CCT GCT GAA CCT GAG GAT GTG AGG GAC TAC CTC CTG TAC CTG CAAGCC AGA GGC CTG GCT GTG AAG ACC ATC CAA CAG CAC CTG GGC CAG CTC AAC ATG CTGCAC AGG AGA TCT GGC CTG CCT CGC CCT TCT GAC TCC AAT GCT GTG TCC CTG GTG ATGAGG AGA ATC AGA AAG GAG AAT GTG GAT GCT GGG GAG AGA GCC AAG CAG GCC CTG GCCTTT GAA CGC ACT GAC TTT GAC CAA GTC AGA TCC CTG ATG GAG AAC TCT GAC AGA TGCCAG GAC ATC AGG AAC CTG GCC TTC CTG GGC ATT GCC TAC AAC ACC CTG CTG CGC ATTGCC GAA ATT GCC AGA ATC AGA GTG AAG GAC ATC TCC CGC ACC GAT GGT GGG AGA ATGCTG ATC CAC ATT GGC AGG ACC AAGACC CTG GTG TCC ACA GCT GGT GTG GAG AAG GCCCTG TCC CTG GGG GTT ACC AAG CTG GTG GAG AGA TGG ATC TCT GTG TCT GGT GTG GCTGAT GAC CCC AAC AAC TAC CTG TTC TGC CGG GTC AGA AAG AAT GGT GTG GCT GCC CCTTCT GCC ACC TCC CAA CTG TCC ACC CGG GCC CTG GAA GGG ATC TTT GAG GCC ACC CACCGC CTG ATC TAT GGT GCC AAG GAT GAC TCT GGG CAG AGA TAC CTG GCC TGG TCT GGCCAC TCT GCC AGA GTG GGT GCT GCC AGG GAC ATG GCC AGG GCT GGT GTG TCC ATC CCTGAA ATC ATG CAG GCT GGT GGC TGG ACC AAT GTG AAC ATT GTG ATG AAC TAC ATC AGAAAC CTG GAC TCT GAG ACT GGG GCC ATG GTG AGG CTG CTC GAG GAT GGG GAC

[0053] Step S3: Microinjection

[0054] The gRNA (50 ng / μl), Cas9 mRNA (100 ng / μl), and targeting vector (50 ng / μl) were mixed and microinjected into the pronucleus of C57BL / 6 mouse zygotes. The injection volume for each zygote was approximately 2 μl. The injected zygotes were cultured in KSOM medium to the blastocyst stage and then transferred to the oviduct of pseudopregnant recipient mice. After a gestation period of approximately 19-21 days, F0 generation mice were obtained.

[0055] Step S4: Genotyping of F0 generation mice

[0056] At 3 weeks of age, approximately 0.5 cm of tail tip tissue was harvested from F0 generation mice, and genomic DNA was extracted using an alkaline lysis method. The specific procedures are as follows:

[0057] (1) Place the tail tip tissue into an EP tube containing 500 μl of alkaline lysis buffer (25 mM NaOH, 0.2 mM EDTA);

[0058] (2) Heat at 95℃ for 30 min to fully lyse the tissue;

[0059] (3) After cooling to room temperature, add 500 μl of neutralization solution (40 mM Tris-HCl, pH 5.0) and mix well;

[0060] (4) Centrifuge at 13000 rpm for 5 min and take the supernatant as a PCR template.

[0061] Design three primer pairs for PCR identification:

[0062] Primer pair 1 (5' end identification):

[0063] Forward: 5'-CCTTTGGTCTGATGATTTCCC-3' (located upstream of the 5' homologous arm)

[0064] Reverse: 5'-TGCCAATGTGGATCAGCATTC-3' (located within the 3×FLAG sequence)

[0065] Expected amplified fragment size: approximately 1.8 kb

[0066] Primer pair 2 (3' end identification):

[0067] Forward: 5'-CACTGACTTTGACCAAGTCAGATC-3' (located within the iCre sequence)

[0068] Reverse: 5'-GGACATGCATAGTCAAAGTCATG-3' (located downstream of the 3' homologous arm)

[0069] Expected amplified fragment size: approximately 2.0 kb

[0070] Primer pair 3 (internal identification):

[0071] Forward: 5'-ACCTGGTGGCTAGTATGAGGC-3' (located within the P2A sequence)

[0072] Reverse: 5'-GTGTCCCAGACAGGTTATAACACAGG-3' (located within the iCre sequence)

[0073] Expected amplified fragment size: approximately 1.2 kb

[0074] PCR amplification system (25 μl):

[0075] Forward primer (10 μM): 1 μl

[0076] Reverse primer (10 μM): 1 μl

[0077] DNA template: 1 μl

[0078] 2×PCR reaction mixture: 12.5 μl

[0079] ddH2O: 9.5 μl

[0080] PCR amplification procedure:

[0081] Pre-denaturation at 95℃ for 5 min;

[0082] The process involved 20 cycles: denaturation at 95℃ for 30 seconds, annealing at 65℃ for 30 seconds, and extension at 72℃ for 30 seconds (with the annealing temperature decreasing by 0.5℃ in each cycle).

[0083] The process involved denaturation at 95℃ for 30 seconds, annealing at 55℃ for 30 seconds, and extension at 72℃ for 30 seconds, for a total of 15 cycles.

[0084] The final extension was at 72℃ for 5 minutes.

[0085] PCR products were detected by 1.5% agarose gel electrophoresis. Individuals that amplified bands of the expected size were considered positive. Positive PCR products were sent for sequencing to verify the accuracy of the inserted sequence.

[0086] Step S5: Obtaining F1 generation mice

[0087] F0 generation positive mice (sexually mature, approximately 8-10 weeks old) were mated with wild-type C57BL / 6 mice. Male positive mice were housed with 2-3 wild-type female mice, or female positive mice were housed with wild-type male mice in a 1:1 ratio. The female mice's vaginal plugs were observed, and the mating date was recorded. F1 generation mice were obtained 19-21 days after conception.

[0088] Step S6: Genotyping of F1 generation mice;

[0089] Step S7: Functional Verification

[0090] TrpA1-3×FLAG-P2A-iCre heterozygous mice were crossed with Rosa26-loxP-stop-loxP-tdTomato (Rosa26-LSL-tdTomato) reporter mice to obtain double-positive offspring. Mice were sacrificed at 8 weeks of age, and brain tissue was collected for the following tests:

[0091] (1) Preparation of frozen sections:

[0092] The tissue was fixed overnight with 4% paraformaldehyde, dehydrated overnight with 30% sucrose solution, embedded in OCT, sectioned on a cryostat (10 μm thick), and attached to a glass slide.

[0093] (2) Immunofluorescence staining:

[0094] Sections were washed with PBS, permeabilized with 0.3% Triton X-100 for 10 min, and blocked with 5% normal donkey serum at room temperature for 1 h. Primary antibody (rabbit anti-RFP antibody, 1:500 dilution) was added and incubated overnight at 4°C. After washing with PBS, secondary antibody (donkey anti-rabbit Alexa Fluor 555, 1:1000 dilution) was added and incubated at room temperature for 2 h. Cell nuclei were counterstained with DAPI, mounted, and observed under a fluorescence microscope.

[0095] (3) Results analysis:

[0096] In brain slices, tdTomato-positive cells were observed in the cortex and hippocampus, exhibiting a distinct red fluorescent signal. This indicates that the Cre recombinase can effectively function in TrpA1-expressing cells, thereby mediating the specific expression of the reporter gene. This expression pattern is largely consistent with previously reported TrpA1 distribution, further validating the good accuracy and functional reliability of the TrpA1-3×FLAG-P2A-iCre mouse constructed in this invention.

[0097] Experimental results showed that the positive rate of the F0 generation in TrpA1-3×FLAG-P2A-iCre gene knock-in mice was approximately 15–25%, and the F1 generation inheritance conformed to Mendelian inheritance laws. Immunofluorescence results indicated that the tdTomato reporter gene was specifically expressed in the target tissue, suggesting that the Cre recombinase has good functional activity and expression specificity. This mouse model can be used for research on TrpA1-related neurobiology and pain mechanisms.

Claims

1. A method for constructing a TrpA1-3×FLAG-P2A-iCre gene knock-in mouse, comprising the following steps: S1. Design and in vitro transcribe and synthesize gRNA and Cas9 mRNA targeting the end of exon 27 of the TrpA1 gene; S2. Construct a targeting vector containing 3×FLAG-P2A-iCre insert sequences and homologous arms; S3. gRNA, Cas9 mRNA and the targeting vector were co-microinjected into C57BL / 6 mouse zygotes; S4. Extract DNA from the tails of F0 generation mice, and screen positive individuals by PCR amplification and sequencing; S5. Cross F0 generation positive mice with wild-type mice to obtain F1 generation heterozygous mice; S6. Genotyping of F1 generation mice; S7. TrpA1-3×FLAG-P2A-iCre heterozygous mice were crossed with Cre reporter mice, and the function of Cre recombinase and the distribution of TrpA1-expressing cells were verified by immunofluorescence or immunohistochemical staining.

2. The method for constructing a TrpA1-3xFLAG-P2A-iCre knock-in mouse according to claim 1, wherein: The target sequences of the gRNA described in step S1 are AAGACACAGAACTAAAAGTC and AGACACAGAACTAAAAGTCC, which are designed at the end of exon 27 of the TrpA1 gene to achieve precise gene editing.

3. The method for constructing a TrpA1-3xFLAG-P2A-iCre knock-in mouse according to claim 1, wherein: The targeting vector described in step S2 includes a 5' homologous arm, a 3×FLAG tag coding sequence, a P2A autorepeptide sequence, an iCre recombinase coding sequence, and a 3' homologous arm, enabling site-specific integration of exogenous fragments through homologous recombination.

4. The method for constructing the TrpA1-3×FLAG-P2A-iCre gene knock-in mouse as described in claim 1, characterized in that: Step S4, the PCR identification, uses three pairs of primers to amplify the 5' end, 3' end, and the internal sequence of the inserted fragment, respectively.

5. The method for constructing the TrpA1-3×FLAG-P2A-iCre gene knock-in mouse as described in claim 1, characterized in that: The functional verification in step S7 involves sectioning and immunostaining tissues known to express TrpA1, and confirming the functionality and expression specificity of Cre recombinase using tdTomato fluorescence signal.